Zorilla CD, Matos M, Morales A, Bonano JF; International Conference on AIDS.
Int Conf AIDS. 2000 Jul 9-14; 13: abstract no. WePpB1303.
C.D. Zorilla, UPR School of Medicine, PO Box 365067, San Juan, Puerto Rico 00936-5067, Puerto Rico, Tel.: 787-753-5913, Fax: 787-764-7881, E-mail: C_ZORRILLA@RCMACA.UPR.CLU.EDU
Background: Pregnant women living with HIV are currently offered Highly Active AntiRetroviral Therapy (HAART) according to current reccomendations for treatment in adults. We reviewed the experience of women with pregnancies treated with either dual (ZDV/3TC) or triple (HAART) in 97-99. Methods: Chart abstraction of 77 pregnant women and their infants delivered between 1997 and 1999. Two tretment options: dual (ZDV/3TC) or triple (ZDV/3TC and a Protease Inhibitor-PI) therapy were offered according to clinical status. A trend towards more aggressive use of HAART is evident through this 3 year period. Results: None of the 61 infants born to date is HIV infected. The mean Birth Weight was 3,170 gm. The rate of pre-term deliveries (>37 weeks GA) was 20% for each group. 93% of the mothers in the PI group and 85% of the dual therapy delivered at 35 weeks or more. Of the women receiving dual therapy (n = 42) the mean CD4 pretherapy was 476, the mean Viral Load (VL) pretherapy was 10,400 copies/per ml, 66% had a VL >1000 at delivery, 35% had a VL >500 at delivery. Of the women receiving triple (HAART) (n = 35) the mean CD4 pretherapy was 365, the mean VL pretherapy was 48,533, 77% had a VL >1000 at delivery, 70% had a VL >500 at delivery. One third of all the women were on therapy prior to conception, and 50% were started during the second trimester. During 1996, 9% of the women were on HAART, which increased to 46% in 1997, 61% in 1998 and 86% in 1999. The transmission rate was zero in both groups and there was liberal use of the elective C-section (55% and 57% respectively). Conclusions: The use of HAART was associated with a higher proportion of undetectable viremia at delivery, therefore suggesting a potential long-term maternal benefit of such therapy. A trend towards more aggressive use of HAART was seen in this retrospective review of which 86% are currently offered HAART. No HIV transmission was seen and the perinatal outcome was good.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Adult
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Birth Weight
- Female
- HIV
- HIV Infections
- HIV Seropositivity
- Humans
- Infant
- Lamivudine
- Pregnancy
- Pregnancy Complications, Infectious
- Pregnancy Outcome
- Viral Load
- Zidovudine
Other ID:
UI: 102240307
From Meeting Abstracts